Skip to main content

Table 2 Demographics of PNH patients at baseline compared to general population

From: Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

Variable

Began trial on eculizumab (n = 219)

Began trial on ravulizumab (n = 222)

General population (n = 15,386)

Mean

SD

Mean

SD

Mean

SD

Age

47.38

15.30

45.67

14.83

53.57

15.375

Years Since Diagnosis

8.93

8.84

9.33

8.70

NA

 

Baseline BMI (kg/m2)

25.25

4.23

24.83

4.71

  
 

#

%

#

%

#

%

Region

      

 Europe

113

51.60

106

47.75

13,373

86.92

 Japan

22

10.05

25

11.26

0

0.00

 Latin America

13

5.94

9

4.05

0

0.00

 North America

16

7.31

17

7.66

2013

13.08

 Rest of Asia  Pacific

55

25.11

65

29.28

0

0.00

Female

102

46.58

107

48.20

7650

49.72